Revaprazan Explained
| Iupac Name: | N-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-2-pyrimidinamine |
| Tradename: | Revanex[1] |
| Cas Number: | 199463-33-7 |
| Unii: | 5P184180P5 |
| Atc Prefix: | None |
| Pubchem: | 204104 |
| Chemspiderid: | 176801 |
| Synonyms: | YH1885 |
| C: | 22 |
| H: | 23 |
| F: | 1 |
| N: | 4 |
| Smiles: | c1cc(F)ccc1Nc2nc(C)c(C)c(n2)N3CCc4ccccc4C3C |
| Stdinchi: | 1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26) |
| Stdinchikey: | LECZXZOBEZITCL-UHFFFAOYSA-N |
Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in South Korea,[4] but is not approved in Europe or the United States.
See also
Notes and References
- Web site: Revaprazan . drugs.com.
- J Gastroenterol Hepatol . Oct 2010 . 25 . 10 . 1618–1625 . 10.1111/j.1440-1746.2010.06408.x . Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects . Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS . 20880169. 41932174 .
- Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers . Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS . J Clin Pharmacol . Jan 2004 . 44 . 1 . 73–82 . 14681344 . 10.1177/0091270003261321. 19658496 .
- Web site: Revaprazan Yuhan registered, South Korea (gastritis) . https://web.archive.org/web/20140429190723/http://business.highbeam.com/436989/article-1G1-151758768/revaprazan-yuhan-registered-south-korea . dead . April 29, 2014 . R & D Focus Drug News . September 25, 2006.
